Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Korn, A. Thielen, S. Seyfried, O. Kornmann, R. Buhl (Mainz, Nuremberg, Germany). Treatment of uncontrolled, severe persistent allergic (IgE-mediated) asthma with omalizumab in a real-life setting in Germany. Eur Respir J 2008; 32: Suppl. 52, 2013

Member's Comments

No comment yet.

Related content which might interest you: Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 The ’real-life’ long-term efficacy of omalizumab in severe persistent IgE-mediated allergic asthma in Malta Source: International Congress 2016 – Asthma management Year: 2016 Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care Year: 2007 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 3 UK centres Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 4 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 Immunotherapy in severe asthma Source: ERS webinar 2021: Immunotherapy in severe asthma Year: 2021 Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021 Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Omalizumab improves lung function in severe persistent allergic (IgE-mediated) asthma patients: Pooled data from 5 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Anti-IgE treatment: An alternative for severe allergic occupational asthma Source: Annual Congress 2012 - Asthma and COPD at work: what are the effects of exposure and risk factors? Year: 2012